AI-guided treatment for newly diagnosed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether a computer-guided treatment plan can work as well as or better than the standard chemo-immunotherapy for large B-cell lymphoma. It uses a special test after the first cycle to decide who needs a more aggressive approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old and in generally good health.
- You must have a type of lymphoma called large B-cell lymphoma (LBCL) that has not been treated yet.
- Your cancer must be CD20-positive, which means it has a specific protein on the cells.
- You must have at least one tumor or lymph node that can be measured on scans.
- You must not have serious heart, liver, or kidney problems.
- You must be willing to provide a written consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an AI-based tool can help choose the best treatment for older adults with large B-cell lymphoma who are not fit for standard chemotherapy. It compares a personalized AI strategy with a standard two-drug regimen.
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.